Moderna (MRNA) Update Implies Phase 3 Data in Oct/Nov Timeframe - Jefferies
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $90.00 price target on Moderna (NASDAQ: MRNA) after the company provided ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
